Holen Sie sich die Stockscreener-App
0.00
100.00%
-5.00
2 Seventy Bio Inc Aktie (TSVT) Neueste Nachrichten
How 2seventy bio Inc. stock performs during market volatilityControlled Entry Strategy With Safety Analytics - Newser
Long term hold vs stop loss in 2seventy bio Inc.Free Safe Entry Stock Watch Suggestions - Newser
Analyzing net buyer seller activity in 2seventy bio Inc.Swing Gain Strategy with Entry Forecast - Newser
Momentum divergence signals in 2seventy bio Inc. chartFree Weekly Hot Picks With Buy Confidence - Newser
Live Scanner Shows Breakout on 2seventy bio Inc.Watchlist for Smart Swing Trading Updated - metal.it
What drives 2seventy bio Inc. stock priceAchieve rapid portfolio growth with expert guidance - Jammu Links News
How does 2seventy bio Inc. compare to its industry peersFree Stock Market Forecast Reports - Jammu Links News
2seventy bio Inc. Stock Analysis and ForecastConsistent double returns - Jammu Links News
What are the technical indicators suggesting about 2seventy bio Inc.Achieve rapid financial growth with expert help - Jammu Links News
What are analysts’ price targets for 2seventy bio Inc. in the next 12 monthsDiscover breakthrough trading strategies - Jammu Links News
How many analysts rate 2seventy bio Inc. as a “Buy”Explosive portfolio gains - Jammu Links News
Should I hold or sell 2seventy bio Inc. stock in 2025Superior trading gains - Jammu Links News
How does 2seventy bio Inc. generate profit in a changing economyCapitalize on market momentum for maximum gains - Jammu Links News
What is the dividend policy of 2seventy bio Inc. stockCapitalize on fast-growing investment opportunities - Jammu Links News
What makes 2seventy bio Inc. stock price move sharplyConsistently superior profits - Jammu Links News
Is 2seventy bio Inc. stock overvalued or undervaluedHigh-profit stock alerts - Jammu Links News
Why is 2seventy bio Inc. stock attracting strong analyst attentionUnbelievable profit margins - Jammu Links News
What are the latest earnings results for 2seventy bio Inc.Get expert insights on market-moving stocks - Jammu Links News
When is 2seventy bio Inc. stock expected to show significant growthSpectacular growth rates - Jammu Links News
Is 2seventy bio Inc. Stock a Good Fit for Conservative InvestorsBuy Alerts With Low Risk Confirmation Noted - metal.it
Is 2seventy bio Inc. forming a reversal patternTechnical Stock Breakout Predictions Signal Entry Points - metal.it
Momentum Screeners Rank 2seventy bio Inc. in Top 5 TodayAlpha Driven Watchlist With Alerts Published - metal.it
Heatmap Data Shows High Activity in 2seventy bio Inc. SectorReal Time Alerts Based on AI Prediction Triggered - metal.it
Sector Leaders Rotate Capital Into 2seventy bio Inc.Breakout Confirmation With Entry Tracker Enabled - metal.it
2seventy bio Inc. Company’s Quarterly Earnings Growth: What the Numbers SayAI Powered Stock Call - metal.it
What catalysts could drive 2seventy bio Inc. stock higher in 2025Track emerging stocks with high growth potential - Jammu Links News
How strong is 2seventy bio Inc. company’s balance sheetAchieve consistent double-digit growth - Jammu Links News
Published on: 2025-07-27 15:37:28 - Jammu Links News
Can 2seventy bio Inc. stock recover from recent declineExplosive earning power - Jammu Links News
Why 2seventy bio Inc. stock attracts strong analyst attentionTop Performing Stocks - beatles.ru
Is 2seventy bio Inc. a good long term investmentDynamic investment growth - Jammu Links News
Krystal Biotech doses first patient in EMERALD-1 phase 1/2 trial for neurotrophic keratitis - Ophthalmology Times
FDA Accepts NDA for Zoliflodacin, Potentially First Gonorrhea Antibiotic in Decades - Managed Healthcare Executive
Cigna Launches AI Tools to Simplify Health Insurance, Improve Customer Experience - Managed Healthcare Executive
FDA Approves Ibtrozi For Adults With ROS1+ NSCLC - Managed Healthcare Executive
Alachua bio-manufacturing plant to lay off employees ahead of shutdown - WCJB | TV20
'Life is too short to work on things that are mediocre': Why this biotech CEO's 2nd drug approval is a big deal - The Business Journals
Taletrectinib Gains FDA Approval for Locally Advanced or Metastatic ROS1+ NSCLC - Pharmacy Times
Bonnie Hui-Callahan, Pharm.D., Video Interview | 2025 MHE Emerging Leaders in Healthcare - Managed Healthcare Executive
Wellington Management Group LLP Reduces Stock Position in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
BNP Paribas Financial Markets Makes New Investment in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Deutsche Bank AG Has $1.10 Million Stock Position in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
MHE Week in Review –Medicaid Bill Mayhem, UnitedHealth’s Stock Plummets and More - Managed Healthcare Executive
Raymond James Financial Inc. Makes New $52,000 Investment in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
2Seventy Bio Reports Strong Q1 2025 Earnings - TipRanks
Investor relations - Bristol Myers Squibb
Wells Fargo & Company MN Has $96,000 Stake in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
2seventy bio Completes Merger, Delists from Nasdaq - TipRanks
Earnings call transcript: Nuvation Bio Q1 2025 sees strategic focus amid EPS miss - Investing.com India
2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb - Business Wire
Stelara Biosimilar Yesintek Gains Coverage on Leading Formularies - Managed Healthcare Executive
Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden - Yahoo Finance
Yearly Depression Screening for Young Adults Is Worth the Cost - Managed Healthcare Executive
Brokerages Set 2seventy bio, Inc. (NASDAQ:TSVT) Price Target at $5.60 - Defense World
0.71%
0.30%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):